Label For One: FDA Explores Taking Reservations For Brand Names
This article was originally published in The Pink Sheet Daily
Executive Summary
Request for information indicates agency’s approach to allow sponsors to hold proprietary names pre-approval may still be too tepid for industry.
You may also be interested in...
Drug Proprietary Name Selection: Draft Guidance Calls For Simulation Studies
FDA draft guidance on developing proprietary drug names recommends series of steps for sponsors to evaluate a proposed name; safety review includes testing name with healthcare professionals.
What’s In A Name? Janssen’s Loss Of Sovriad Was Gilead’s Gain With Sovaldi
FDA initially rejected both sponsors’ preferred proprietary names for their hepatitis C treatments due to the risk of confusion with each other. Janssen had to settle for Olysio, its backup name for simeprevir, leaving Gilead to claim title to its preferred name for sofosbuvir.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.